Compare SDA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDA | BMEA |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | China | United States |
| Employees | 544 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.4M | 95.4M |
| IPO Year | N/A | 2021 |
| Metric | SDA | BMEA |
|---|---|---|
| Price | $0.78 | $1.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $4.75 | ★ $9.83 |
| AVG Volume (30 Days) | 277.1K | ★ 1.0M |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $15.55 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $0.87 |
| 52 Week High | $2.93 | $2.99 |
| Indicator | SDA | BMEA |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 51.07 |
| Support Level | $0.72 | $1.23 |
| Resistance Level | $0.97 | $1.46 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 27.84 | 40.32 |
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform. Revenues from its continuing operations are mainly generated from providing auto eInsurance services, technology services, and auto services.
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.